BioCentury
ARTICLE | Clinical News

Brilinta: Phase IIIb data

October 10, 2016 7:00 AM UTC

Top-line data from the double-blind, international Phase IIIb EUCLID trial in 13,885 symptomatic patients with PAD showed that twice-daily 90 mg oral Brilinta missed the primary endpoint of improving ...